Cazares v. Ortho El Paso, P.A.

District Court, W.D. Texas·Decided August 7, 2020·No. 3:20-cv-00005·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF TEXAS EL PASO DIVISION JAVIER CADENA § CAZARES and ANGELINA § CAZARES, § Plaintiffs, § § v. § EP-20-CV-5-PRM § ORTHO EL PASO, P.A., § CVS HEALTH INC. d/b/a § CVS, CVS CAREMARK, § INC. d/b/a CVS, GENCO § PHARMACEUTICAL § SERVICES, AVENTIS § INC., AVENTIS § PHARMACEUTICAL, INC., § SANOFI SA, SANOFI U.S., § SANOFI-AVENTIS, § SANOFI-AVENTIS LLC, § SANOFI-AVENTIS U.S. § LLC, SANOFI U.S. § SERVICES INC., SANOFI § PASTEUR, SANOFI § GENZYME, GENZYME § CORPORATION, § GENZYME BIOSURGERY, § Defendants. § MEMORANDUM OPINION AND ORDER ACCEPTING IN PART AND REJECTING IN PART THE REPORT AND RECOMMENDATION OF THE MAGISTRATE JUDGE On this day, the Court considered the Magistrate Judge’s “Report and Recommendation” (ECF No. 22) [hereinafter “R. & R.”], filed on June 12, 2020; Defendants CVS Health Inc. d/b/a CVS, CVS Caremark,

Inc. d/b/a CVS, Genco Pharmaceutical Services, Aventis Inc., Aventis Pharmaceutical, Inc., Sanofi SA, Sanofi U.S., Sanofi-Aventis, Sanofi- Aventis LLC, Sanofi-Aventis U.S. LLC, Sanofi U.S. Services Inc., Sanofi

Pasteur, Sanofi Genzyme, Genzyme Corporation, Genzyme Biosurgery’s [hereinafter “Removing Defendants”] “Objection to the Report and Recommendation” (ECF No. 23) [hereinafter “Removing Defendants’

Objection”], filed on June 24, 2020; Defendant Ortho El Paso P.A.’s [hereinafter “Defendant Ortho El Paso”] “Objection to Report and Recommendation” (ECF No. 24) [hereinafter “Defendant Ortho El

Paso’s Objection”], filed on June 24, 2020; and Plaintiffs’ “Response to the Non-Diverse Defendant’s Objections to the Report and Recommendation” (ECF No. 25), filed on June 26, 2020, in the above-

captioned cause. In its R. & R., the Magistrate Judge recommended granting Plaintiffs Javier Cadena Cazares and Angelina Cazares’s [hereinafter

“Plaintiffs”] “Motion to Remand” (ECF No. 4), filed on February 7, 2020. R. & R. 1. Further, the Magistrate Judge recommended that in the event the Court adopts the R. & R. and grants Plaintiffs’ Motion to Remand, that the Court refrain from ruling on Defendant Ortho El

Paso’s “Motion to Dismiss for Failure to State a Claim Upon Which Relief May be Granted” (ECF No. 10) [hereinafter “Motion to Dismiss”], filed on February 25, 2020. Id. at 21. Alternatively, if the Court denies

the Motion to Remand, the Magistrate Judge recommended that the Court deny the Motion to Dismiss as moot. Id. After due consideration, the Court is of the opinion that for the reasons set forth below, the R. &

R. should be accepted in part and rejected in part, Plaintiffs’ Motion to Remand should be denied, and Defendant Ortho El Paso’s Motion to Dismiss should be denied as moot.

I. FACTUAL AND PROCEDURAL BACKGROUND A. State Court Proceedings This case arises out of a personal injury claim. Plaintiffs allege

that Plaintiff Javier Cazares sustained injuries after receiving an injection of “the drug Synvisc-One® (Hylan g-f20).” Notice of Removal Ex. A, at 5, Jan. 8, 2020, ECF No. 1. Named Defendants are

“manufacturers, designers, producers, marketers, sellers, handlers, and/or distributors” of Synvisc-One®.” Id. Plaintiffs assert that a batch of Synvisc-One® syringes that “had been produced at Defendants’ plant and distributed between October 25, 2017 and November 7, 2017” had

become contaminated. Id. Plaintiffs further claim that Plaintiff Javier Cazares received an injection from the contaminated batch of Synvisc-One® syringes,

resulting in the instant suit: On November 9, 2017, Mr. Cazares was suffering from osteoarthritis in his knee. Plaintiff's doctor, working from Defendant Ortho El Paso's facility where the drug was ultimately distributed and sold for final use, administered a dose of contaminated Synvise-One® to Mr. Cazares for his knee pain. The contaminated syringe was placed into the stream of commerce by all named Defendants, who at all times relevant to this lawsuit, maintained exclusive control of the manufacture, distribution, sale, and administration of the bacteria-infused Synvisc-One®. Due to the bacterial cocktail he was injected with, Mr. Cazares suffered an immediate adverse reaction and subsequent infection that eventually necessitated several surgeries, months of therapy, and numerous hospitalizations. As a result of the injuries caused by the Defendants, both Plaintiffs sustained severe injuries described below.

Id. at 5. Plaintiffs bring claims of strict liability, manufacturing defect, negligence, breach of express warranty, and breach of the implied warranties of merchantability and fitness for particular purpose, against several named defendants. Id. at 6–9. Against Defendant Ortho El Paso specifically, Plaintiffs assert the product liability claims of strict liability, implied breach of warranty, and express breach of

warranty.1 See id. (refraining from including Defendant Ortho El Paso in its negligence or manufacturing defect claims). B. Removal, Motion to Remand, and Motion to Dismiss

Plaintiffs initially filed suit in the 34th Judicial District Court in El Paso County, Texas, on November 8, 2019, and filed their “First Amended Petition” (ECF No. 1-1) [hereinafter “Petition”], on January 2,

2020. Id. at 2. The case was then removed to the United States District Court for the Western District of Texas, El Paso Division, on January 8, 2020, by Removing Defendants. Id. at 1–2; Notice of Removal Ex. B, at

2–5. Removing Defendants contend that removal is proper based on 28 U.S.C. § 1332 diversity jurisdiction. Notice of Removal 2. Further,

1 The Court recognizes that Removing Defendants’ second objection is that Plaintiffs did not properly assert these claims against Defendant Ortho El Paso in their state-court Petition. Removing Defs.’ Obj. 9. However, for the purposes of the Court’s analysis of Removing Defendants’ first objection, the Court assumes, without deciding, that Plaintiffs properly alleged these claims against Defendant Ortho El Paso in their Petition in state court. This assumption is accordant with the strict approach courts must take in assessing the propriety of removal. See Manguno v. Prudential Prop. And Cas. Ins. Co., 276 F.3d 720, 723 (5th Cir. 2002) (“Any ambiguities are construed against removal because the removal statute should be strictly construed in favor of remand.”) (citing Acuna v. Brown & Root, Inc., 200 F.3d 335, 339 (5th Cir. 2000)). Removing Defendants aver that the presence of Defendant Ortho El

Paso, a Texas citizen, does not destroy diversity of the parties because Defendant Ortho El Paso was improperly joined to the lawsuit.2 Id. at 3–8.

On February 7, 2020, Plaintiffs filed their “Motion to Remand” (ECF No. 4), arguing that the Court does not have subject matter jurisdiction. In particular, Plaintiffs allege that the case lacks complete

diversity because Defendant Ortho El Paso is a proper party to the suit. Mot. to Remand 5. Thereafter, Removing Defendants’ filed their “Response in Opposition to Plaintiffs’ Motion to Remand” (ECF No. 7)

[hereinafter “Response to Motion to Remand”] on February 13, 2020. Defendant Ortho El Paso filed its “Motion to Dismiss for Failure to State a Claim Upon Which Relief May be Granted” (ECF No. 10)

[hereinafter “Motion to Dismiss”] on February 25, 2020, refuting Plaintiffs’ Motion to Remand by raising essentially the same arguments as those found in Removing Defendants’ Notice of Removal and

Response to Motion to Remand. Thereafter, Plaintiffs filed their “Response to Defendant Ortho El Paso P.A.’s Untimely Motion to

Free access — add to your briefcase to read the full text and ask questions with AI

Cazares v. Ortho El Paso, P.A., (W.D. Tex. 2020).

Cazares v. Ortho El Paso, P.A. (Cazares v. Ortho El Paso, P.A.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Oppenheimer v. Prudential Securities Inc.
94 F.3d 189 (Fifth Circuit, 1996)
Spivey v. Robertson
197 F.3d 772 (Fifth Circuit, 1999)
Acuna v. Brown & Root Inc.
200 F.3d 335 (Fifth Circuit, 2000)
Howery v. Allstate Ins Company
243 F.3d 912 (Fifth Circuit, 2001)
Manguno v. Prudential Property & Casualty Insurance
276 F.3d 720 (Fifth Circuit, 2002)
Travis v. Irby
326 F.3d 644 (Fifth Circuit, 2003)
Stoner v. New York Life Insurance
311 U.S. 464 (Supreme Court, 1941)
Thomas v. Arn
474 U.S. 140 (Supreme Court, 1986)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Burr Stafford v. Mobil Oil Corporation
945 F.2d 803 (Fifth Circuit, 1991)
Hadley v. WYETH LABORATORIES, INC.
287 S.W.3d 847 (Court of Appeals of Texas, 2009)
Easterly v. HSP of Texas, Inc.
772 S.W.2d 211 (Court of Appeals of Texas, 1989)
Walden v. Jeffery
907 S.W.2d 446 (Texas Supreme Court, 1995)
Cobb v. Dallas Fort Worth Medical Center-Grand Prairie
48 S.W.3d 820 (Court of Appeals of Texas, 2001)
Nevauex v. Park Place Hospital, Inc.
656 S.W.2d 923 (Court of Appeals of Texas, 1983)